European Union & European Union — European Medicines Agency
22 shared events · Importance 3 · Last updated Aug 24, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
European Union: The European Union is securing emergency deliveries of favipiravir and launching procurement procedures for additional doses to address the hantavirus outbreak.
European Union — European Medicines Agency: The European Union — European Medicines Agency identified favipiravir as the most plausible candidate for hantavirus treatment under clinical trial or compassionate use protocols.
May 28, 2026 · 6 articles
Regulatory
European Union: The European Union is the region where the marketing authorization for TAVNEOS is being revoked, affecting patients and pharmaceutical companies operating within its borders.
European Union — European Medicines Agency: The European Union — European Medicines Agency's CHMP recommended the revocation of the marketing authorization for TAVNEOS, impacting its availability in the EU.
Jun 26, 2026 · 9 articles
Business
European Union: The European Union is a key market where Imlifidase is conditionally approved and where the PAES study was conducted, leading to the upcoming application for full marketing authorization.
European Union — European Medicines Agency: The European Union — European Medicines Agency conditionally approved Imlifidase and requested the PAES study, which has now been successfully completed, paving the way for a full marketing authorization application.
May 27, 2026 · 6 articles
Regulatory
European Union: The European Union represents the market where DAYBU is seeking approval, and its member states will be affected by the potential marketing authorization.
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) is the overarching regulatory body whose CHMP adopted the positive opinion for DAYBU, facilitating its potential market entry in the EU.
Jun 26, 2026 · 6 articles
Regulatory
European Union: The EU is the region where DAYBU is now approved, covering 27 member states and providing a new treatment option for Rett syndrome patients.
European Union — European Medicines Agency: The EMA's advisory committee recommended approval, which preceded the International — European Commission's decision.
Aug 24, 2026 · 7 articles
Domestic
European Union: France's decision makes it the first European Union country to fund weight-loss drugs, potentially setting a precedent for other member states to follow.
European Union — European Medicines Agency: The European Union — European Medicines Agency recently recommended approval of Novo Nordisk's Semaglutide pill, which could pave the way for the first oral weight-loss drug in Europe, complementing France's reimbursement initiative.
May 28, 2026 · 6 articles
Business
European Union: The European Union>>> is a key region where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
European Union — European Medicines Agency: The European Union — European Medicines Agency>>> is involved in the approval process for Imlifidase>>>, with a payment contingent on its filing acceptance.
May 19, 2026 · 7 articles
Business
European Union: The EU is another major market for PentixaFor, with regulatory support from the EMA and a large patient population.
European Union — European Medicines Agency: The EMA granted PRIME status to PentixaFor, providing enhanced support for its development and approval in European Union — Europe.
Jul 15, 2026 · 10 articles
Business
European Union: The EU is a major territory covered by the licensing agreement, with all 27 member states included, representing a significant market opportunity.
European Union — European Medicines Agency: The EMA accepted the Marketing Authorisation Application for senaparib, a regulatory step that is critical for European Union — European market entry. Approval is expected in H2 2026.
Jul 31, 2026 · 8 articles
Regulatory
European Union: The European Union is a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the region.
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) is mentioned as a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the European Union.
Jun 25, 2026 · 6 articles
Business
European Union: The European Union represents a significant market where Dyne Therapeutics is seeking approval for zeleciment basivarsen, supported by the Orphan Drug designation from the European Union — European Medicines Agency.
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) has granted Orphan Drug designation to zeleciment basivarsen, indicating Dyne Therapeutics' pursuit of approval pathways outside of the U.S.
Jun 03, 2026 · 6 articles
Business
European Union: Regulatory jurisdiction where EMA PRIME designation and Orphan Drug designation were granted.
European Union — European Medicines Agency: Granted PRIME designation for lacutamab in Sézary syndrome, supporting accelerated assessment.
Aug 10, 2026 · 10 articles
Business
European Union: The EU is a region where Idefirix has conditional approval, contributing to the product's overall commercial base.
European Union — European Medicines Agency: The EMA's prior conditional approval and PRIME designation support Idefirix's regulatory standing in Europe, though not directly impacted by this event.
Aug 18, 2026 · 6 articles
Regulatory
European Union: The European Union>>> is a market where the European Union — European Medicines Agency>>> has validated a Marketing Authorization Application for AVT16 and AVT80.
European Union — European Medicines Agency: The European Union — European Medicines Agency>>> has validated a Marketing Authorization Application for AVT16 and AVT80, indicating progress in European markets.
Jun 08, 2026 · 11 articles
Business
European Union: Region where Palsonify received approval.
European Union — European Medicines Agency: Approved Palsonify for acromegaly in the EU.
Jul 06, 2026 · 34 articles
Business
European Union: The European Union is mentioned as a bloc with which India has concluded talks for a free trade agreement, highlighting India's ongoing efforts to expand its trade network.
European Union — European Medicines Agency: Indian generic medicines approved by the European Union — European Medicines Agency>>> will receive fast-track marketing authorization in Oman>>> under the CEPA.
May 29, 2026 · 79 articles
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Dupixent for chronic spontaneous urticaria (CSU) in the European Union.
Feb 24, 2026 · 8 articles
Tech
European Union — European Medicines Agency: The European Union — European Medicines Agency reviewed IDEFIRIX as part of its PRIority Medicines program, supporting its conditional marketing approval in Europe.
May 25, 2026 · 6 articles
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency certifies Abbott Laboratories's manufacturing practices, ensuring compliance with European Good Manufacturing Practices.
Jun 18, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how European Union and European Union — European Medicines Agency interact across events, view sentiment trends, and discover connected entities.
Open Dashboard